Background {#Sec1}
==========

Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by deposition of extracellular lipoproteinaceous material within pulmonary alveoli \[[@CR1]\]. PAP usually results from failure of clearance of surfactant by alveolar macrophages \[[@CR2]--[@CR4]\]. The most common cause of PAP is autoimmune (in 90% of cases, aPAP) relevant to the presence of anti-GM-CSF (Granulocyte-macrophage colony-stimulating factor) autoantibodies. GM-CSF, a growth factor for granulocytes and monocytes, stimulates the differentiation, the proliferation and the survival of myeloid cells \[[@CR5]\]. Anti-GM-CSF antibodies bind with high affinity to GM-CSF thus blocking receptor binding and its specific activity \[[@CR6]--[@CR8]\]. Alveolar macrophages are then no longer able to clear alveolar surfactant, and also have a poor local anti-infectious activity \[[@CR9]\]. The pathogenicity of anti-GM-CSF antibodies has been proven by the development of PAP after administration of anti-GM-CSF antibodies to non human primates \[[@CR10], [@CR11]\].

Whole lung lavage is the current standard therapy for PAP and has been shown to improve the prognosis. Whole lung lavage is effective in almost 85% of patients \[[@CR12]\]. However, whole lung lavage is associated with adverse effects such as infections, fever, convulsions, pneumothorax, pleural effusion, hypoxemia or even death. Moreover, 15% of patients do not improve and 10% of patients need repeated whole lung lavage \[[@CR13]--[@CR19]\]. Corticosteroids are not effective and may be associated with an increased risk of opportunistic infection \[[@CR20]\]. Inhaled or sub-cutaneous GM-CSF is currently investigated as an alternative to therapeutic lung lavage (NCT02702180). Retrospective and prospective data suggest a persistent improvement in 48% to 100% of the cases \[[@CR21]--[@CR23]\]. Rituximab, a monoclonal antibody directed against the CD20 antigen, has been shown to be effective in several autoimmune diseases such as rheumatoid arthritis or granulomatosis with polyangiitis \[[@CR24]--[@CR26]\]. Rituximab has been reported to improve aPAP in 3 isolated cases and in 7/9 patients of a prospective series \[[@CR27]--[@CR30]\]. While, rituximab showed early promising results and appears to be an interesting alternative treatment, we aimed to evaluate its efficacy on aPAP in real life.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

We retrospectively identified all French patients with aPAP who received rituximab between 2007 and 2014, from a mailing list to the French network of competence and reference centers for rare pulmonary diseases. In France, almost all of the patients with rare lung diseases, and particularly with aPAP, are referred to one of the competence/reference center.

All patients gave informed consent for data collection and the use of rituximab beyond marketing authorization. The Institutional Review Board of the French-learned society for respiratory medicine (Société de Pneumologie de Langue Française) approved this retrospective study (CEPRO 2012--016).

Inclusion criteria {#Sec4}
------------------

The patients were included in the study if 1) they had evidence for PAP as assessed by bronchoalveolar lavage (BAL), transbronchial biopsy or open lung biopsy; and 2) an anti-GM-CSF antibody was detected; and 3) they had received at least one dose of rituximab.

Data collection {#Sec5}
---------------

The clinical charts of the patients were reviewed and the following data were collected by use of a standardized and anonymous collection form: at the first rituximab infusion (day 0 or baseline), and at day 14, at months 3 (M3), M6, M9, M12. We collected clinical data, standard biological tests results, anti-GM-CSF antibodies titer, chest high-resolution computed tomography (CT), and results of lung function tests, and blood gases when available.

Anti-GM-CSF titer {#Sec6}
-----------------

GM-CSF neutralizing activity of serum was evaluated in a functional bioassay \[[@CR4]\]. Briefly, the GM-CSF-dependent TF-1 cell line was incubated with serial serum dilutions in the presence of 1 ng/mL recombinant GM-CSF (Cellgenix, Germany). After 48 h incubation, ^3^H-thymidine was added for further 8 h. Thymidine uptake by TF-1 cells was assessed by quantification of the radioactivity with a scintillation counter. The GM-CSF antibody titer was calculated as the inverse of the serum dilution blocking 50% of the maximum TF-1 proliferation.

In addition, in some patients, the serum GM-CSF antibody concentration was assessed by ELISA as previously described \[[@CR4], [@CR31], [@CR32]\], with some modifications. Briefly, 96-wells Maxisorp® plates (Corning, USA) were coated overnight with 1 μg/mL GM-CSF in phosphate buffer saline (PBS) then washed with PBS-0.05% Tween and blocked with PBS-1% bovine serum albumin for 2 h. After 3 washing steps, diluted sera were added to the wells and incubated for 40 min at room temperature. Then wells were washed 5 times with PBS-0.1% Tween and bound GM-CSF antibodies were detected by anti-human IgG biotinylated antibody (BD Pharmingen, USA) combined to streptavidin conjugated to horseradish peroxidase. Chromogenic substrate solution (TMB Substrate Reagent, BD Pharmingen) was added. Optical absorbance was measured at 450 nm. Anti-GM-CSF concentration was calculated using a standard calibration curve obtained with human polyclonal intravenous immunoglobulins.

All assays were done in one single expert center. Functional assays were done at time of blood taking, while ELISA measurements were done for all samples at the same time.

Chest CT analysis {#Sec7}
-----------------

Chest CT obtained before (baseline), or 6 months and 12 months after rituximab infusion, were anonymously analyzed by an experienced thoracic radiologist (MPD), patient by patient, blinded to the time from treatment. The extent of CT reticulations and ground-glass opacities was scored between 6 and 30 by summing the grades of 6 pulmonary zones (adapted from \[[@CR33]\]). The more extended the CT lesions, the higher the score.

Assessments {#Sec8}
-----------

Improvement after rituximab therapy was defined by a decrease ≥10 mmHg of the alveolar--arterial gradient at rest (D(A-a)O~2~) as compared to baseline. A deterioration was defined by an increase ≥10 mmHg of the D(A-a)O~2~.

Other endpoints considered as significantly improved were: ≥ 10 mmHg increase of arterial partial pressure of oxygen (PaO~2~), ≥ 10% increase in diffusing capacity of the lung for carbon monoxide (DLCO) or absolute value of vital capacity (VC), ≥ 50% decrease in GM-CSF antibody level, ≥ 3 points decrease in CT-grade. The disease severity score (DSS) was assessed as follow: DSS 1: no symptoms and PaO2 ≥ 70 mmHg, DSS 2: symptomatic and PaO2 ≥ 70 mmHg, DSS 3: PaO2 ≥ 60 mmHg and \< 70 mmHg, DSS 4: PaO2 ≥ 50 mmHg and \< 60 mmHg and DSS 5: PaO2 \< 50 mmHg \[[@CR22]\].

Statistical analysis {#Sec9}
--------------------

Continuous data are presented as mean (minimum-maximum) and compared by the Mann-Whitney's test. Categorical data are presented as numbers (%) and compared by the Fisher's test. All tests were bilateral with a *p* \< 0.05 considered as significant. All analyses were performed with the GraphPAd prism software (La Jolla, USA).

Results {#Sec10}
=======

Patients {#Sec11}
--------

We identified a total of 13 patients (9 men) from 11 centers, including one patient previously reported \[[@CR28]\] (Table [1](#Tab1){ref-type="table"}). The mean age at aPAP diagnosis was 46 years and the mean time since diagnosis was 28.5 months. Seven patients (54%) were smokers, including 4 active smokers, and 8 patients (62%) had been exposed to inhaled toxics.Table 1Patients characteristics at inclusionPatients12345678910111213Age (year)44565030534149445941514945GenderMMMFMFMFFMMMMDuration of PAP (months)381212296450632915452051Smoking statusNeverNeverCurrentCurrentNeverNeverNeverNeverExCurrentExExCurrentInhaled toxicNoNoYesYesYesNoYesNoYesYesYesYesNoPrevious therapyNoWLL\
GM-CSFWLLWLLWLL\
GM-CSFWLL\
GM-CSFNoWLL\
GM-CSFWLLWLLWLL\
GM-CSFWLLNoInitial Improvement with WLLNpNoNoYesYesYesNpYesNoNoNoYesNpAggravation in the 3 month before RTXYesNoYesYesNoYesYesNoYesYesYesYesYesDisease severity score3222243422323Anti GM-CSF titer before RTX10,0004804007001000200400400403003008004000D(a-A)O2At RTX injection36364038315046573735473540At M122032605130Na356038Na152627*PAP* Pulmonary alveolar proteinosis, *M* Male, *F* Female, *WLL* Whole Lung lavage, *RTX* Rituximab, *Na* Not available, *Np* not performedFor patients without dosage at rituximab injection, the last available concentration of anti-GM-CSF is reported

Prior to rituximab, 10 patients (77%) were treated with whole lung lavage, with a mean of 2.8 lavages and a median of 2.0 lavages per patient. No patient received whole lung lavage within 3 months before inclusion. Five patients (38%) had received GM-CSF prior to rituximab, including one who was still treated by inhaled GM-CSF at first infusion of rituximab.

Rituximab therapy and efficacy {#Sec12}
------------------------------

Twelve patients received two infusions of rituximab (1000 mg) (at day 0 and day 14) among whom three received a third infusion at month 6, 9 and 12 respectively. One patient received only one infusion of rituximab (1000 mg) and was lost to follow-up after month 3. One patient was treated with plasma exchange one month after enrollment, and then received a lung transplant. Eleven patients were still followed from M3 (Table [2](#Tab2){ref-type="table"}).Table 2Characteristics at inclusion and after rituximabMean valuesAt Rituximab injectionAfter rituximab*p*-value\*M3M6M12Number of patients13111111D(A-a)O~2~ (mmHg)40 (31--57)43 (34--60)40 (31--56)35.9 (15--60)0.19PaO~2~ (mmHg)68 (57--82)63 (55--70)65 (52--78)70 (49--92)0.51Disease Severity Score2.7 (2--4)3.0 (2--4)2.8 (2--4)2.3 (1--5)0.44VC (%predicted value)79 (36--100)78 (61--87)79 (50--100)84 (62--102)0.81DLCO (% predicted value)54 (19--92)46 (30--86)50 (29--79)63 (35--97)0.38Serum anti-GM-CSF ELISA (μg/mL)/Available99 (18--220)/8Na85 (19--187)/77.7 (3.1--158)/60.19 Functional (titer)/Available853 (200--4000)/9Na831 (30--4000)/11436 (0--1400)/80.21CT-grade19.3 (12--28)Na19.3 (13--28)17.3 (6--26)0.73\*between at rituximab injection and M12, *VC* Vital capacity, *DLCO* Diffusing capacity of the lung for carbon monoxide, *CT* Computed tomography, *D(A-a)O*~*2*~ alveolar--arterial gradient at rest~,~ *na* not available

In the whole population, rituximab was not associated with significant improvement in any of the endpoints at M3, M6 or M12 (Table [2](#Tab2){ref-type="table"}). However when assessed individually some patients did improve (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Changes in D(A-a)O~2~ before (D0) and 6 (M6) et 12 (M12) months after rituximab therapy

At M6 after rituximab infusion, 3 patients deteriorated their lung function and required whole lung lavage or GM-CSF therapy. D(A-a)O~2~, PaO2 or VC was not improved in any patient. DLCO improved in one patient and CT scan improved in two patients.

At M12 after rituximab infusion, a significant improvement of D(A-a)O~2~ was observed in 4/11 patients (36%, none of them had received any additional therapy after rituximab), while D(A-a)O~2~ was stable in 5 patients (45%, including 2 patients who received specific aPAP therapies because of an early deterioration) and decreased in 2 patients (18%). In the improved group, the mean D(A-a)O~2~ decreased from 42.4 mmHg before infusion to 24.3 mmHg at M12 and the mean PaO~2~ get from 64.3 mmHg before infusion to 82.8 mmHg at M12 (Table [3](#Tab3){ref-type="table"}). In parallel, at M12, VC increased in 1/10 patients (10%), DLCO in 5/10 patients (50%), and CT score decreased in 4/9 patients (44%). Three patients had both increased DLCO and D(A-a)O~2~ and decreased CT score.Table 3Factors associated with therapeutic response in patients evaluated at M12Improved (*n* = 4)Non-improved (*n* = 7)*p*-valueAge47 (41--51)48 (30--59)0.70Gender male4 (100%)4 (57%)0.24Toxics inhalation or significant smoking3 (75%)5 (71%)1.0Prior treatments to rituximab1 (25%)7 (100%)0.02Severity PaO~2~ (mmHg)64.3 (63--66)70.7 (57--82)0.07 D(A-a)O~2~ (mmHg)42.4 (36.7--46)39.4 (31.7--57.7)0.32 VC (%)94.3 (85--105)83.0 (54--95)0.92 DLCO (%)49.0 (19--64)56.9 (38--92)0.30 CT-grade17.8 (12--23)20.1 (14--28)0.50Serum anti-GM-CSF ELISA (μg/mL)169.3 (78--220)58.2 (18--104)0.03 Functional (titer)1566.7 (300--4000)496.7 (200--800)1.0*VC* Vital capacity, *DLCO* Diffusing capacity of the lung for carbon monoxide, *CT* Computed tomography, *D(A-a) O*~*2*~ alveolar--arterial gradient at rest

Evolution of anti-GM-CSF titers {#Sec13}
-------------------------------

Data were both available at rituximab injection and at M12 for 6 patients evaluated by the functional assay and 4 patients evaluated by ELISA.

Globally, the mean level of anti-GM-CSF antibodies was not significantly modified before and after rituximab, evaluated either by ELISA or by functional assay (Table [2](#Tab2){ref-type="table"}). However, 4 patients (67%) showed a significant decrease (≥ 50%) of anti-GM-CSF antibody titers at M12 as evaluated by the functional assay, among which 2 showed an improvement of D(A-a)O~2~, while 1 patient (25%) showed a significant decrease of anti-GM-CSF antibody titers as evaluated by ELISA, and this patient did not experience improvement of D(A-a)O~2~.

Characteristics of patients who improved after rituximab {#Sec14}
--------------------------------------------------------

We assessed the characteristics of patients who improved defined by a decrease ≥10 mmHg of the alveolar--arterial gradient at rest (D(A-a)O~2~) at M12 as compared to baseline. The patients who improved were four men aged 45 to 51 years. Three were current or ex-smokers and one of them was exposed to wool dusts and bird feathers. There was no significant difference between improved and non-improved patients on age, gender, smoking history or toxic inhalation, and disease severity at rituximab initiation. Patients who improved had higher serum titers of anti-GM-CSF antibodies evaluated by ELISA, received less specific aPAP therapies prior to rituximab and tended to have lower PaO~2~ at inclusion (Table [3](#Tab3){ref-type="table"}). None of the patients who improved received adjuvant PAP therapy in the 12 months following rituximab infusion.

Adverse events {#Sec15}
--------------

No serious adverse events related to rituximab were identified. A cutaneous rash or pruritus occurred after the first rituximab administration in 3 patients, and spontaneously resolved. One patient developed deep-vein thrombosis and one patient complained of sleep and concentration troubles. During follow-up, 2 patients developed viral upper respiratory tract infection and one patient was given a diagnosis of *Mycobacterium avium* airway colonization. No opportunistic infection was observed.

Discussion {#Sec16}
==========

This series is the largest series evaluating rituximab in aPAP. Rituximab was well tolerated and adverse effects were rare and minor. Rituximab was associated with an objective improvement in only 4 of the 13 patients treated (30%) after 12 months. Interestingly, improvement only occurred after 6 months of treatment and was more frequent in patients naive of specific aPAP therapy and with higher level of GM-CSF auto-antibodies evaluated by ELISA.

One prospective clinical trial by Kavuru et al., which included 9 aPAP patients, reported a 78% objective response at M12 \[[@CR29]\]. In the current series, the absence of a significant improvement after rituximab in the whole population and the 30% objective response were disappointing. Numerous hypotheses may explain this discrepancy between both series. Firstly, the patients included in the current series were less hypoxemic (mean initial PaO~2~: 68 mmHg) than those studied by Kavuru et al. (PaO~2~: 54 mmHg) \[[@CR29]\]. Interestingly, we observed that patients who improved had lower initial PaO~2~ than patients who did not improve (*p* = 0.07). Secondly, in the current series, patients who already received a specific therapy for aPAP were less prone to respond, although patients from the Kavuru et al. trial had received a mean of 5 whole lung lavage before inclusion \[[@CR29]\]. Some of the patients from the present series may present irreversible interstitial lung disease or pulmonary fibrosis, although we were not able to identify them by CT scan \[[@CR34]\].

Our study showed that the improvement of the D(A-a)O~2~ was delayed after rituximab infusion, as it was only evidenced at M12 while it was absent at M6. Again, our results are discordant with Kavuru et al. who showed an improvement of D(A-a)O~2~, PaO~2~, pulmonary function tests and CT-scan from M6 \[[@CR29]\]. Such a delayed efficacy of rituximab is not reported in other autoimmune diseases such as autoimmune hemolytic anemia or ANCA associated vasculitis. This delayed effect could be due to 1) the time needed to restore a normal alveolar macrophagic activity, that may be delayed from circulating monocyte activity and 2) to the time needed to evidence a functional effect of an improved alveolar surfactant clearance \[[@CR35]\].

We cannot exclude that rituximab was not responsible for the improvement observed in 4 patients at M12, since spontaneous improvement has been reported in up to 30% of cases in the literature. Spontaneous improvement is mostly observed in patients with PaO~2~ \> 70 mmHg, D(A-a)O~2~ \< 40 mmHg and with higher DLCO \[[@CR13], [@CR17], [@CR19], [@CR36]\]. In the current series, mean initial PaO~2~ in the responder group was 64 mmHg, D(A-a)O~2~ was 42 mmHg, and DLCO was 49%.

This study has obvious limits such as its uncontrolled and retrospective nature and the relatively small number of patients studied. However, all French patients that received rituximab for aPAP were included in this study and therefore the 30% in intention to treat rate of response is a real life evaluation of rituximab efficacy in this very rare disease.

Conclusions {#Sec17}
===========

This retrospective study does not support rituximab as a second line therapy for patients with refractory aPAP. Since whole lung lavage and inhaled GM-CSF are already very effective for this rare disease, the evaluation of rituximab as a first line therapy is unlikely due to its unconfirmed slowly developing effect.
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